The pharma industry’s quest for profits is what is driving up drug prices, confirms Dennis Bourdette, M.D., chair of neurology in the Oregon Health and Science University (OHSU) School of Medicine. Bourdette recently co-authored a study that sought to find out companies’ rationale for the escalating prices of drugs for patients with multiple sclerosis (MS). The study was based on interviews with pharma executives who had direct involvement in the pricing or marketing of MS drugs.
It is now more than 20 years since Dr. Rath first exposed the criminal nature of the pharmaceutical ‘business with disease’ to the world. In a groundbreaking speech given in the German city of Chemnitz in 1997, he revealed how the pharma industry’s business model required the continued existence of diseases as a means of expanding its markets. Describing the intentional maintenance of diseases as a criminal violation of human rights, Dr. Rath stated that drug companies should be subjected to investigation regarding the extent to which they had enriched themselves from this.
While it was rare in those days to hear this type of open criticism of the pharma industry, today it has become commonplace. Millions of people worldwide now realize that drug companies are primarily driven not by improving human health, but by the profits they make for their shareholders. Dr. Rath has played a major role in bringing this understanding to the attention of the people of the world.
Ultimately, of course, the problem isn’t simply that drugs are too expensive, but also that they only address the symptoms of diseases. To prevent and eradicate diseases safely and effectively it is necessary to address their primary causes. Here too, Dr. Rath has brought a revolutionary new understanding to the fields of medicine and preventive healthcare, which promises to save millions of lives. To learn about it, visit the Cellular Medicine section of our website.